Daré Bioscience (DARE) Price & Analysis

Compare

1,872 Followers

DARE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.83 - $9.19

Previous CloseN/A

Volume4.87K

Average Volume (3M)189.05K

Market Cap

$27.63M

Enterprise Value$24.27M

Total Cash (Recent Filing)$10.33M

Total Debt (Recent Filing)$3.57M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Nov 06, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding13,479,502

10 Day Avg. Volume125,917

30 Day Avg. Volume189,049

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.88

Enterprise Value/Revenue936.61

Enterprise Value/Gross Profit-1.71

Enterprise Value/Ebitda-1.11

Forecast

1Y Price Target

$10.33

Price Target Upside396.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsDaré Bioscience announced positive interim results from its ongoing P3 study of Ovaprene, a non-hormonal monthly contraceptive, with results showing a pregnancy rate in line with or better than current contraceptive methods.

FinancingUpgrading shares of Daré Bioscience to Buy following a capital raise that should secure runway into 2H26, resolving its financing overhang.

Product LaunchThe commercial launch of topical sildenafil through the 503(B) pathway later this year represents a key near-term catalyst.

Bears Say

Funding NeedsAdditional capital will likely be needed, and potentially significantly dilutive, to fund Daré's programs, including the P3 program for topical sildenafil.

Recruitment ChallengesEnrollment in the study was negatively affected by NIH cuts, causing recruitment at NIH CCTN sites to be paused.

Daré Bioscience News

Dare Bioscience upgraded to Buy from Hold at Maxim

Maxim analyst Jason McCarthy upgraded Dare Bioscience (DARE) to Buy from Hold with an $8 price target Published...

15d ago

DARE

Daré, AMD, Twilio, UiPath, Luckin: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($DARE) ), ( ($AMD) ), ( ($TWLO) ), ( ($PATH)...

13d ago

AMD

DARE

Daré Bioscience Engages Market with New Presentation

Daré Bioscience ( ($DARE) ) has shared an announcement. Daré Bioscience, Inc. announced that it will use a...

17d ago

DARE

Daré Bioscience’s Earnings Call: Optimism Amid Challenges

Daré Bioscience (($DARE)) has held its Q2 earnings call. Read on for the main highlights of the call....

19d ago

DARE

Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch

Daré Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from...

1M ago

DARE

Daré Bioscience Announces Q2 2025 Financial Results

Daré Bioscience ( ($DARE) ) has released its Q2 earnings. Here is a breakdown of the information Daré...

1M ago

DARE

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

Dare Bioscience (DARE) and Rosy Wellness announced the launch of the first phase of a consumer awareness campaign...

2M ago

DARE

Daré Bioscience Meets Nasdaq Equity Requirement

An announcement from Daré Bioscience ( ($DARE) ) is now available. On July 24, 2025, Daré Bioscience received...

2M ago

DARE

Dare Bioscience to host webinar on Sildenafil cream

Dare Bioscience (DARE) announced a live webinar on Wednesday, August 6, 2025, titled “The DARE to PLAY Difference:...

2M ago

DARE

Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties

Maxim Group analyst Jason McCarthy has maintained their neutral stance on DARE stock, giving a Hold rating today....

2M ago

DARE

3 Penny Stocks to Watch Now, 7/15/25

Dare Bioscience, LQR House, and Canaan Inc. are the 3 Penny Stocks to watch on July 15, 2025, based on TipRanks’...

2M ago

CAN

LQR

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

Daré Bioscience stock soared higher on Monday alongside positive interim data from a Phase 3 study. ...

2M ago

DARE

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

The trading week has only just begun, and already there’s plenty of stock market news worth reading in...

2M ago

Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene

Dare Bioscience (DARE) announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating...

2M ago

DARE

DARE FAQ

What was Daré Bioscience Inc’s price range in the past 12 months?

Daré Bioscience Inc lowest stock price was $1.83 and its highest was $9.19 in the past 12 months.

What is Daré Bioscience Inc’s market cap?

Daré Bioscience Inc’s market cap is $27.63M.

When is Daré Bioscience Inc’s upcoming earnings report date?

Daré Bioscience Inc’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.

How were Daré Bioscience Inc’s earnings last quarter?

Daré Bioscience Inc released its earnings results on Aug 14, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.58 by $0.13.

Is Daré Bioscience Inc overvalued?

According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Daré Bioscience Inc pay dividends?

Daré Bioscience Inc does not currently pay dividends.

What is Daré Bioscience Inc’s EPS estimate?

Daré Bioscience Inc’s EPS estimate is -0.39.

How many shares outstanding does Daré Bioscience Inc have?

Daré Bioscience Inc has 13,479,502 shares outstanding.

What happened to Daré Bioscience Inc’s price movement after its last earnings report?

Daré Bioscience Inc reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.58. Following the earnings report the stock price went up 6.28%.

Which hedge fund is a major shareholder of Daré Bioscience Inc?

Currently, no hedge funds are holding shares in DARE

Company Description

Daré Bioscience Inc

Daré Bioscience, Inc. is a clinical-stage biotechnology company focused on advancing innovative products for women's health. The company develops therapeutic solutions aimed at addressing unmet medical needs in areas such as contraception, sexual health, and reproductive health. With a portfolio that includes a range of product candidates, Daré aims to improve the quality of life for women through innovative and effective healthcare solutions.

Daré Bioscience (DARE) Earnings & Revenues

Historic Earnings Reports

DARE Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in Daré's dual-path strategy and upcoming product launches, which are expected to drive revenue and expand their market presence. However, technical difficulties during the call and a working capital deficit were noted. Overall, the sentiment is optimistic with a focus on future growth.View all DARE earnings summaries

DARE Stock 12 Month Forecast

Average Price Target

$10.33

▲(396.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.796923076923077,3.5638461538461534,4.3307692307692305,5.0976923076923075,5.864615384615385,6.631538461538462,7.398461538461538,8.165384615384616,8.932307692307692,9.69923076923077,10.466153846153846,11.233076923076922,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.668461538461538,3.306923076923077,3.9453846153846155,4.583846153846154,5.222307692307693,5.860769230769231,6.499230769230769,7.1376923076923084,7.776153846153846,8.414615384615384,9.053076923076924,9.691538461538462,{"y":10.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.489230769230769,2.9484615384615385,3.4076923076923076,3.8669230769230767,4.326153846153846,4.785384615384615,5.2446153846153845,5.703846153846154,6.163076923076924,6.622307692307693,7.081538461538463,7.5407692307692304,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.42,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >